March 15, 2018 / 10:50 AM / 2 years ago

Alexion's rare blood disorder drug succeeds in late-stage study

March 15 (Reuters) - Alexion Pharmaceuticals Inc said its experimental drug, ALXN1210, met the main goal in a late-stage study in patients with a rare blood disorder.

The drug, ALXN1210, was being tested against the company’s flagship drug Soliris. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below